Cargando…
The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells
BACKGROUND: Previous studies with BIT225 (N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide) have demonstrated a unique antiviral activity that blocks the release of HIV-1 from monocyte-derived macrophages (MDM). Antagonising the ion channel formed by HIV-1 Vpu, BIT225 preferentially target...
Autores principales: | Khoury, Gabriela, Ewart, Gary, Luscombe, Carolyn, Miller, Michelle, Wilkinson, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745167/ https://www.ncbi.nlm.nih.gov/pubmed/26858771 http://dx.doi.org/10.1186/s12981-016-0093-z |
Ejemplares similares
-
The HIV-1 Vpu Viroporin Inhibitor BIT225 Does Not Affect Vpu-Mediated Tetherin Antagonism
por: Kuhl, Björn D., et al.
Publicado: (2011) -
Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2
por: Ewart, Gary, et al.
Publicado: (2023) -
Looking a bit superficial to the pleura
por: Blanco, Pablo, et al.
Publicado: (2014) -
EE225 Economic and Clinical Impact of a Novel, Antiviral Therapy on COVID-19 in the US
por: Gibson, S, et al.
Publicado: (2022) -
Bit by Bit: The Darwinian Basis of Life
por: Joyce, Gerald F.
Publicado: (2012)